Edge Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Edge Capital Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,138	Closed	-$282K	–	373
2022 Q1	$282K	Hold	3,138	–	–	0.02%	255
2021 Q4	$351K	Hold	3,138	–	–	0.02%	225
2021 Q3	$394K	Hold	3,138	–	–	0.03%	209
2021 Q2	$425K	Sell	3,138 -239	-7%	-$31.4K	0.03%	201
2021 Q1	$458K	Buy	+3,377	New	+$506K	0.04%	185

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Edge Capital Group's XBI Position: Q2 2022 in Review

Edge Capital Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 3,138 shares — an estimated $282K sold.

Edge Capital Group first reported a position in XBI in Q1 2021 and held it in 5 quarters. The position peaked at $458K in Q1 2021. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Edge Capital Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Edge Capital Group sold 3,138 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $282K.
Edge Capital Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 5 quarters.
Edge Capital Group's State Street SPDR S&P Biotech ETF position peaked at $458K in Q1 2021.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Edge Capital Group's 13F filing for Q2 2022, filed 8 Aug 2022.